US4235871A
(en)
|
1978-02-24 |
1980-11-25 |
Papahadjopoulos Demetrios P |
Method of encapsulating biologically active materials in lipid vesicles
|
DE3381783D1
(de)
|
1982-03-03 |
1990-09-13 |
Genentech Inc |
Menschliches antithrombin iii, dns sequenzen dafuer, expressions- und klonierungsvektoren die solche sequenzen enthalten und damit transformierte zellkulturen, verfahren zur expression von menschlichem antithrombin iii und diese enthaltende pharmazeutische zusammensetzungen.
|
US4452773A
(en)
|
1982-04-05 |
1984-06-05 |
Canadian Patents And Development Limited |
Magnetic iron-dextran microspheres
|
US4501728A
(en)
|
1983-01-06 |
1985-02-26 |
Technology Unlimited, Inc. |
Masking of liposomes from RES recognition
|
US5019369A
(en)
|
1984-10-22 |
1991-05-28 |
Vestar, Inc. |
Method of targeting tumors in humans
|
US4690915A
(en)
|
1985-08-08 |
1987-09-01 |
The United States Of America As Represented By The Department Of Health And Human Services |
Adoptive immunotherapy as a treatment modality in humans
|
US4795698A
(en)
|
1985-10-04 |
1989-01-03 |
Immunicon Corporation |
Magnetic-polymer particles
|
IN165717B
(fr)
|
1986-08-07 |
1989-12-23 |
Battelle Memorial Institute |
|
US4837028A
(en)
|
1986-12-24 |
1989-06-06 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
US5219740A
(en)
|
1987-02-13 |
1993-06-15 |
Fred Hutchinson Cancer Research Center |
Retroviral gene transfer into diploid fibroblasts for gene therapy
|
US5565566A
(en)
|
1987-04-24 |
1996-10-15 |
Discovery Therapeutics, Inc. |
N6 -substituted 9-methyladenines: a new class of adenosine receptor antagonists
|
US5606040A
(en)
|
1987-10-30 |
1997-02-25 |
American Cyanamid Company |
Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
|
US5770701A
(en)
|
1987-10-30 |
1998-06-23 |
American Cyanamid Company |
Process for preparing targeted forms of methyltrithio antitumor agents
|
US5298508A
(en)
|
1988-07-19 |
1994-03-29 |
The United States Of America As Represented By The Department Of Health And Human Services |
Irreversible inhibitors of adenosine receptors
|
AU4746590A
(en)
|
1988-12-28 |
1990-08-01 |
Stefan Miltenyi |
Methods and materials for high gradient magnetic separation of biological materials
|
CA2026147C
(fr)
|
1989-10-25 |
2006-02-07 |
Ravi J. Chari |
Agents cytotoxiques comprenant des maytansinoides et leur usage therapeutique
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
US5283173A
(en)
|
1990-01-24 |
1994-02-01 |
The Research Foundation Of State University Of New York |
System to detect protein-protein interactions
|
US5200084A
(en)
|
1990-09-26 |
1993-04-06 |
Immunicon Corporation |
Apparatus and methods for magnetic separation
|
ATE159548T1
(de)
|
1990-11-13 |
1997-11-15 |
Immunex Corp |
Bifunktionelle wählbare fusionsgene
|
US5424297A
(en)
|
1992-04-27 |
1995-06-13 |
University Of Virginia Alumni Patents Foundation |
Adenosine dextran conjugates
|
DE4228458A1
(de)
|
1992-08-27 |
1994-06-01 |
Beiersdorf Ag |
Multicistronische Expressionseinheiten und deren Verwendung
|
CA2149329C
(fr)
|
1992-11-13 |
2008-07-15 |
Darrell R. Anderson |
Utilisation d'anticorps hybrides et radioisotopiques diriges contre l'antigene de restriction de la differenciation des lymphocytes b humains pour le traitement du lymphome b
|
US5635483A
(en)
|
1992-12-03 |
1997-06-03 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Tumor inhibiting tetrapeptide bearing modified phenethyl amides
|
US5780588A
(en)
|
1993-01-26 |
1998-07-14 |
Arizona Board Of Regents |
Elucidation and synthesis of selected pentapeptides
|
US5629327A
(en)
|
1993-03-01 |
1997-05-13 |
Childrens Hospital Medical Center Corp. |
Methods and compositions for inhibition of angiogenesis
|
AU6781194A
(en)
|
1993-05-03 |
1994-11-21 |
United States Of America, Represented By The Secretary, Department Of Health And Human Services, The |
8-substituted 1,3,7-trialkyl-xanthine derivatives as a2-selective adenosine receptor antagonists
|
EP0804590A1
(fr)
|
1993-05-21 |
1997-11-05 |
Targeted Genetics Corporation |
Genes de fusion selectables et bifonctionnels se basant sur le gene de cytosine-deaminase (cd)
|
US5504090A
(en)
|
1994-03-30 |
1996-04-02 |
Trustees Of The University Of Pennsylvania |
Compositions and methods for the prevention and treatment of ischemia-reperfusion organ injury
|
US5773001A
(en)
|
1994-06-03 |
1998-06-30 |
American Cyanamid Company |
Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
|
US5827642A
(en)
|
1994-08-31 |
1998-10-27 |
Fred Hutchinson Cancer Research Center |
Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
|
US5670501A
(en)
|
1994-09-01 |
1997-09-23 |
Discovery Therapeutics, Inc. |
N-substituted 9-alkyladenines
|
US5712374A
(en)
|
1995-06-07 |
1998-01-27 |
American Cyanamid Company |
Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
|
US5714586A
(en)
|
1995-06-07 |
1998-02-03 |
American Cyanamid Company |
Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
|
JP4431638B2
(ja)
|
1996-01-29 |
2010-03-17 |
アメリカ合衆国 |
ジヒドロピリジン―、ピリジン―、ベンゾピラン―オン―およびトリアゾロキナゾリン誘導体、それらの製造およびそれらのアデノシン受容体アンタゴニストとしての用途
|
GB9603256D0
(en)
|
1996-02-16 |
1996-04-17 |
Wellcome Found |
Antibodies
|
DE19608753C1
(de)
|
1996-03-06 |
1997-06-26 |
Medigene Gmbh |
Transduktionssystem und seine Verwendung
|
WO1997034634A1
(fr)
|
1996-03-20 |
1997-09-25 |
Sloan-Kettering Institute For Cancer Research |
Produits de recombinaison d'anticorps diriges contre le gd2, constitues d'un fragment variable (fv) a chaine simple
|
US5635517B1
(en)
|
1996-07-24 |
1999-06-29 |
Celgene Corp |
Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
|
US6281230B1
(en)
|
1996-07-24 |
2001-08-28 |
Celgene Corporation |
Isoindolines, method of use, and pharmaceutical compositions
|
HU228769B1
(en)
|
1996-07-24 |
2013-05-28 |
Celgene Corp |
Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
|
US5798368A
(en)
|
1996-08-22 |
1998-08-25 |
Celgene Corporation |
Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
|
DK0925294T6
(da)
|
1996-07-24 |
2018-08-20 |
Celgene Corp |
Substituerede 2-(2,6-dioxopiperidin-3-yl)phthalimider og -1-oxoisoindoliner samt fremgangsmåde til reduktion af tnf-alpha-niveauer
|
US6111090A
(en)
|
1996-08-16 |
2000-08-29 |
Schering Corporation |
Mammalian cell surface antigens; related reagents
|
DE69738749D1
(de)
|
1996-08-16 |
2008-07-17 |
Schering Corp |
Zelloberflächen-antigen aus säugetieren und verwandte reagenzien
|
US5786360A
(en)
|
1996-11-19 |
1998-07-28 |
Link Technology Incorporated |
A1 adenosine receptor antagonists
|
CA2293829C
(fr)
|
1997-06-24 |
2011-06-14 |
Genentech, Inc. |
Procedes et compositions concernant des glycoproteines galactosylees
|
US6509173B1
(en)
|
1997-10-21 |
2003-01-21 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor receptor-like proteins TR11, TR11SV1, and TR11SV2
|
DE69840412D1
(de)
|
1997-10-31 |
2009-02-12 |
Genentech Inc |
Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
|
AU2591599A
(en)
|
1998-02-09 |
1999-08-23 |
Genentech Inc. |
Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
|
KR100712573B1
(ko)
|
1998-03-16 |
2007-05-02 |
셀진 코포레이션 |
염증성 사이토카인 억제제용 2-(2,6-디옥소피페리딘-3-일)이소인돌린 유도체, 그 제조방법 및 그 용도
|
JP4843138B2
(ja)
|
1998-04-15 |
2011-12-21 |
ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド |
T細胞阻害性受容体組成物およびその使用
|
DE69942021D1
(de)
|
1998-04-20 |
2010-04-01 |
Glycart Biotechnology Ag |
Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität
|
US6326390B1
(en)
|
1998-08-25 |
2001-12-04 |
King Pharmaceuticals Reseach And Development, Inc. |
Use of adenosine A3 receptor antagonists to inhibit tumor growth
|
CA2343156A1
(fr)
|
1998-09-04 |
2000-03-16 |
Sloan-Kettering Institute For Cancer Research |
Recepteurs de fusion specifiques a l'antigene prostatique specifique membranaire et ses utilisations
|
WO2000023573A2
(fr)
|
1998-10-20 |
2000-04-27 |
City Of Hope |
Cellules modifiees specifiques a la molecule cd20 et utilisation de ces dernieres pour l'immunotherapie cellulaires des malignites cd20?+¿
|
US6232297B1
(en)
|
1999-02-01 |
2001-05-15 |
University Of Virginia Patent Foundation |
Methods and compositions for treating inflammatory response
|
US6313131B1
(en)
|
1999-02-16 |
2001-11-06 |
Upsher-Smith Laboratories, Inc. |
Method of kidney treatment
|
HUP0200499A3
(en)
|
1999-03-18 |
2002-12-28 |
Celgene Corp Warren |
Substituted 1-oxo- and 1,3-dioxoisoindolines and their use for preparation of pharmaceutical compositions for reducing inflammatory cytokine levels
|
EP2270150B2
(fr)
|
1999-04-09 |
2019-08-07 |
Kyowa Hakko Kirin Co., Ltd. |
Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
|
US6322771B1
(en)
|
1999-06-18 |
2001-11-27 |
University Of Virginia Patent Foundation |
Induction of pharmacological stress with adenosine receptor agonists
|
IL147442A0
(en)
|
1999-07-12 |
2002-08-14 |
Genentech Inc |
Promotion or inhibition of angiogenesis and cardiovscularization by tumor necrosis factor ligand/receptor homologs
|
CA2383154C
(fr)
|
1999-08-17 |
2013-04-30 |
Biogen, Inc. |
Recepteur de baff (bcma) et agent immunoregulateur
|
AU7950400A
(en)
|
1999-10-19 |
2001-04-30 |
Kyowa Hakko Kogyo Co. Ltd. |
Process for producing polypeptide
|
AU767394C
(en)
|
1999-12-29 |
2005-04-21 |
Immunogen, Inc. |
Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
|
EP1287357A2
(fr)
|
2000-06-02 |
2003-03-05 |
Memorial Sloan-Kettering Cancer Center |
Cellules presentatrices d'antigene artificiel et leurs methodes d'utilisation
|
US7879328B2
(en)
|
2000-06-16 |
2011-02-01 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to B lymphocyte stimulator
|
KR101155294B1
(ko)
|
2000-06-16 |
2013-03-07 |
캠브리지 안티바디 테크놀로지 리미티드 |
면역특이적으로 BLyS에 결합하는 항체
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
MXPA03002974A
(es)
|
2000-10-06 |
2004-05-05 |
Kyowa Hakko Kogyo Kk |
Celulas que producen composiciones de anticuerpo.
|
US7064191B2
(en)
|
2000-10-06 |
2006-06-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for purifying antibody
|
JP5312721B2
(ja)
|
2000-11-07 |
2013-10-09 |
シティ・オブ・ホープ |
Cd19特異的再指向免疫細胞
|
US6458810B1
(en)
|
2000-11-14 |
2002-10-01 |
George Muller |
Pharmaceutically active isoindoline derivatives
|
US7091353B2
(en)
|
2000-12-27 |
2006-08-15 |
Celgene Corporation |
Isoindole-imide compounds, compositions, and uses thereof
|
US20030045552A1
(en)
|
2000-12-27 |
2003-03-06 |
Robarge Michael J. |
Isoindole-imide compounds, compositions, and uses thereof
|
GB0100624D0
(en)
|
2001-01-10 |
2001-02-21 |
Vernalis Res Ltd |
Chemical compounds VII
|
JP4361273B2
(ja)
|
2001-02-27 |
2009-11-11 |
アメリカ合衆国 |
潜在的な血管形成阻害剤としてのサリドマイド類似体
|
US7070995B2
(en)
|
2001-04-11 |
2006-07-04 |
City Of Hope |
CE7-specific redirected immune cells
|
US20090257994A1
(en)
|
2001-04-30 |
2009-10-15 |
City Of Hope |
Chimeric immunoreceptor useful in treating human cancers
|
CA2838062C
(fr)
|
2001-08-03 |
2015-12-22 |
Roche Glycart Ag |
Variants de glycosylation d'anticorps presentant une cytotoxicite cellulaire accrue dependante des anticorps
|
WO2003035835A2
(fr)
|
2001-10-25 |
2003-05-01 |
Genentech, Inc. |
Compositions de glycoproteine
|
US7939059B2
(en)
|
2001-12-10 |
2011-05-10 |
California Institute Of Technology |
Method for the generation of antigen-specific lymphocytes
|
JP2005516917A
(ja)
|
2001-12-12 |
2005-06-09 |
アメリカ合衆国 |
細胞外アデノシン阻害剤およびアデノシン受容体阻害剤を用いて免疫応答および炎症を増強するための方法
|
US20040093621A1
(en)
|
2001-12-25 |
2004-05-13 |
Kyowa Hakko Kogyo Co., Ltd |
Antibody composition which specifically binds to CD20
|
US20030170238A1
(en)
|
2002-03-07 |
2003-09-11 |
Gruenberg Micheal L. |
Re-activated T-cells for adoptive immunotherapy
|
EP1498491A4
(fr)
|
2002-04-09 |
2006-12-13 |
Kyowa Hakko Kogyo Kk |
Procede d'amelioration de l'activite d'une composition d'anticorps de liaison avec le recepteur fc gamma iiia
|
EA200401325A1
(ru)
|
2002-04-09 |
2005-04-28 |
Киова Хакко Когио Ко., Лтд. |
Клетки с модифицированным геномом
|
JPWO2003085118A1
(ja)
|
2002-04-09 |
2005-08-11 |
協和醗酵工業株式会社 |
抗体組成物の製造方法
|
AU2003236017B2
(en)
|
2002-04-09 |
2009-03-26 |
Kyowa Kirin Co., Ltd. |
Drug containing antibody composition
|
CA2481925A1
(fr)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Agent therapeutique pour les patients atteints du fc.gamma.riiia humain
|
DE60336548D1
(de)
|
2002-04-09 |
2011-05-12 |
Kyowa Hakko Kirin Co Ltd |
Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
|
US7446190B2
(en)
|
2002-05-28 |
2008-11-04 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acids encoding chimeric T cell receptors
|
US20040047858A1
(en)
|
2002-09-11 |
2004-03-11 |
Blumberg Richard S. |
Therapeutic anti-BGP(C-CAM1) antibodies and uses thereof
|
BRPI0316779B8
(pt)
|
2002-12-16 |
2023-02-28 |
Genentech Inc |
Anticorpo anti-cd20 humano ou fragmento de ligação ao antígeno do mesmo, seus usos, composição, artigo manufaturado e formulação líquida
|
EP1576014B1
(fr)
|
2002-12-23 |
2011-06-29 |
Wyeth LLC |
Anticorps anti pd-1 et leurs utilisations
|
US20050129671A1
(en)
|
2003-03-11 |
2005-06-16 |
City Of Hope |
Mammalian antigen-presenting T cells and bi-specific T cells
|
US20050025763A1
(en)
|
2003-05-08 |
2005-02-03 |
Protein Design Laboratories, Inc. |
Therapeutic use of anti-CS1 antibodies
|
US7618632B2
(en)
|
2003-05-23 |
2009-11-17 |
Wyeth |
Method of treating or ameliorating an immune cell associated pathology using GITR ligand antibodies
|
WO2005007190A1
(fr)
|
2003-07-11 |
2005-01-27 |
Schering Corporation |
Agonistes ou antagonistes du recepteur du facteur de necrose tumorale induit par les glucocorticoides (gitr) ou de son ligand utilises dans le traitement des troubles immuns, des infections et du cancer
|
JPWO2005035586A1
(ja)
|
2003-10-08 |
2007-11-22 |
協和醗酵工業株式会社 |
融合蛋白質組成物
|
JPWO2005035778A1
(ja)
|
2003-10-09 |
2006-12-21 |
協和醗酵工業株式会社 |
α1,6−フコシルトランスフェラーゼの機能を抑制するRNAを用いた抗体組成物の製造法
|
DK2330201T3
(en)
|
2003-10-22 |
2017-07-24 |
Keck Graduate Inst |
PROCEDURES FOR SYNTHESIS OF HEATER-MULTIMATE POLYPEPTIDES WHEN USING A HAPLOID COUPLE STRATEGY
|
ES2341009T3
(es)
|
2003-11-05 |
2010-06-14 |
Roche Glycart Ag |
Anticuerpos cd20 con afinidad de union a receptores fc y funcion efectora.
|
NZ583292A
(en)
|
2003-11-06 |
2012-03-30 |
Seattle Genetics Inc |
Monomethylvaline compounds capable of conjugation to ligands
|
JP2007518399A
(ja)
|
2003-12-02 |
2007-07-12 |
ジェンザイム コーポレイション |
肺癌を診断および治療する組成物並びに方法
|
JPWO2005053742A1
(ja)
|
2003-12-04 |
2007-06-28 |
協和醗酵工業株式会社 |
抗体組成物を含有する医薬
|
MXPA06008700A
(es)
|
2004-02-06 |
2007-01-19 |
Morphosys Ag |
Anticuerpos anti-cd38 humanos y usos para los mismos.
|
GB0409799D0
(en)
|
2004-04-30 |
2004-06-09 |
Isis Innovation |
Method of generating improved immune response
|
US20060002932A1
(en)
|
2004-06-04 |
2006-01-05 |
Duke University |
Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
|
US7244759B2
(en)
|
2004-07-28 |
2007-07-17 |
Celgene Corporation |
Isoindoline compounds and methods of making and using the same
|
BRPI0516284A
(pt)
|
2004-09-23 |
2008-09-02 |
Genentech Inc |
anticorpo construìdo com cisteìna, método de selecionar anticorpos, compostos conjugados de droga-anticorpo, composição farmacêutica, método para matar ou inibir a proliferação de células de tumor, métodos de inibir a proliferação celular e o crescimento de células de tumor, artigo manufaturado e método para produzir um composto
|
WO2006099875A1
(fr)
|
2005-03-23 |
2006-09-28 |
Genmab A/S |
Anticorps diriges contre cd38 pour le traitement du myelome multiple
|
US7812135B2
(en)
|
2005-03-25 |
2010-10-12 |
Tolerrx, Inc. |
GITR-binding antibodies
|
KR101339628B1
(ko)
|
2005-05-09 |
2013-12-09 |
메다렉스, 인코포레이티드 |
예정 사멸 인자 1(pd-1)에 대한 인간 모노클로날 항체, 및 항-pd-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법
|
NZ581779A
(en)
|
2005-05-17 |
2011-09-30 |
Univ Connecticut |
Composition and methods for immunomodulation in an organism comprising interleukin-15 polypeptide and interleukin-15 receptor subunit A polypeptide complex
|
KR101888321B1
(ko)
|
2005-07-01 |
2018-08-13 |
이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. |
예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
|
EP2366787B1
(fr)
|
2006-01-13 |
2019-12-11 |
The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services |
Gènes IL-15 et IL-15R-alpha à codon optimisé pour une expression dans les cellules de mammifères
|
EP1981969A4
(fr)
|
2006-01-19 |
2009-06-03 |
Genzyme Corp |
Anticorps anti-gitr destines au traitement du cancer
|
US7960518B2
(en)
|
2006-06-06 |
2011-06-14 |
Crucell Holland B.V. |
Human binding molecules having killing activity against enterococci and uses thereof
|
EP1914242A1
(fr)
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Nouveau anticorps Anti-CD38 pour le traitement du cancer
|
CA2678180A1
(fr)
|
2007-02-13 |
2008-12-04 |
Northeastern University |
Procedes et compositions pour ameliorer les reponses immunitaires
|
UA102994C2
(ru)
|
2007-03-22 |
2013-09-10 |
Дженентек, Инк. |
АНТИТЕЛО, КОТОРОЕ СПЕЦИФИЧНО СВЯЗЫВАЕТСЯ С IgE/M1' И ИНДУЦИРУЕТ АПОПТОЗ В ЭКСПРЕССИРУЮЩИХ IgE В-КЛЕТКАХ
|
SI2856876T1
(en)
|
2007-03-30 |
2018-04-30 |
Memorial Sloan-Kettering Cancer Center |
Constituent expression of costimulatory ligands on indirectly transmitted T lymphocytes
|
US7615883B2
(en)
|
2007-06-06 |
2009-11-10 |
Meheen H Joe |
Wind driven venturi turbine
|
PL2170959T3
(pl)
|
2007-06-18 |
2014-03-31 |
Merck Sharp & Dohme |
Przeciwciała przeciwko ludzkiemu receptorowi programowanej śmierci PD-1
|
EP2173378B1
(fr)
|
2007-06-27 |
2014-03-19 |
Admune Therapeutics LLC |
Complexes d'il-15 et il-15r alpha et leurs utilisations
|
CA2693677C
(fr)
|
2007-07-12 |
2018-02-13 |
Tolerx, Inc. |
Therapies combinees utilisant des molecules de liaison au gitr
|
JP2011500730A
(ja)
|
2007-10-26 |
2011-01-06 |
ガバニング カウンセル オブ ザ ユニバーシティ オブ トロント |
Tim−3を用いた治療および診断方法
|
DK2520643T3
(da)
|
2007-12-07 |
2020-01-20 |
Miltenyi Biotec Bv & Co Kg |
Prøvebehandlingssystemer og -fremgangsmåder
|
CA2710453C
(fr)
|
2007-12-26 |
2019-07-02 |
Biotest Ag |
Agents ciblant cd138 et leurs applications
|
CN101970499B
(zh)
|
2008-02-11 |
2014-12-31 |
治疗科技公司 |
用于肿瘤治疗的单克隆抗体
|
EP2262837A4
(fr)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
Protéines de liaison avec pd-1
|
US20120164718A1
(en)
|
2008-05-06 |
2012-06-28 |
Innovative Micro Technology |
Removable/disposable apparatus for MEMS particle sorting device
|
JP5173594B2
(ja)
|
2008-05-27 |
2013-04-03 |
キヤノン株式会社 |
管理装置、画像形成装置及びそれらの処理方法
|
GB0906579D0
(en)
|
2009-04-16 |
2009-05-20 |
Vernalis R&D Ltd |
Pharmaceuticals, compositions and methods of making and using the same
|
KR20110044992A
(ko)
|
2008-07-02 |
2011-05-03 |
이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 |
TGF-β 길항제 다중-표적 결합 단백질
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
CA2735006A1
(fr)
|
2008-08-25 |
2010-03-11 |
Amplimmune, Inc. |
Antagonistes de pd-1 et leurs procedes d'utilisation
|
PL2350129T3
(pl)
|
2008-08-25 |
2015-12-31 |
Amplimmune Inc |
Kompozycje antagonistów PD-1 i sposoby stosowania
|
US8586023B2
(en)
|
2008-09-12 |
2013-11-19 |
Mie University |
Cell capable of expressing exogenous GITR ligand
|
BRPI0921433A2
(pt)
|
2008-10-31 |
2017-06-06 |
Abbott Biotherapeutics Corp |
uso de anticorpos anti-cs1 para o tratamento de linfomas raros
|
JP2012508017A
(ja)
|
2008-11-07 |
2012-04-05 |
ファブラス エルエルシー |
抗dll4抗体及びその使用
|
WO2010065959A1
(fr)
|
2008-12-05 |
2010-06-10 |
Northeastern University |
Procédé de préparation de lymphocytes t antitumoraux résistants à l'adénosine pour immunothérapie adoptive
|
KR20210060670A
(ko)
|
2008-12-09 |
2021-05-26 |
제넨테크, 인크. |
항-pd-l1 항체 및 t 세포 기능을 향상시키기 위한 그의 용도
|
WO2010104949A2
(fr)
|
2009-03-10 |
2010-09-16 |
Biogen Idec Ma Inc. |
Anticorps anti-bcma
|
PE20120878A1
(es)
|
2009-04-01 |
2012-08-06 |
Genentech Inc |
ANTICUERPOS ANTI-FcRH5 E INMUNOCONJUGADOS
|
PL2424896T3
(pl)
|
2009-04-30 |
2016-03-31 |
Tel Hashomer Medical Res Infrastructure & Services Ltd |
Przeciwciała anty-ceacam1 oraz sposoby ich stosowania
|
ES2598005T3
(es)
|
2009-08-14 |
2017-01-24 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Uso de IL-15 para aumentar la salida del timo y para tratar la linfopenia
|
CA3067609A1
(fr)
|
2009-09-03 |
2011-03-10 |
Merck Sharp & Dohme Corp. |
Anticorps anti-gitr
|
GB0919054D0
(en)
|
2009-10-30 |
2009-12-16 |
Isis Innovation |
Treatment of obesity
|
ES2717629T3
(es)
|
2009-11-03 |
2019-06-24 |
Hope City |
Receptor del factor de crecimiento epidérmico truncado (EGFRt) para selección de células T transducidas
|
US20130017199A1
(en)
|
2009-11-24 |
2013-01-17 |
AMPLIMMUNE ,Inc. a corporation |
Simultaneous inhibition of pd-l1/pd-l2
|
US20130089554A1
(en)
|
2009-12-29 |
2013-04-11 |
Emergent Product Development Seattle, Llc |
RON Binding Constructs and Methods of Use Thereof
|
PT3459564T
(pt)
|
2010-01-06 |
2022-01-31 |
Takeda Pharmaceuticals Co |
Proteínas de ligação à calicreína plasmática
|
JP2011178691A
(ja)
|
2010-02-26 |
2011-09-15 |
Takuya Ueda |
カテニン結合プローブとその用途
|
WO2011159877A2
(fr)
|
2010-06-18 |
2011-12-22 |
The Brigham And Women's Hospital, Inc. |
Anticorps di-spécifiques anti-tim-3 et pd-1 pour immunothérapie dans des états pathologiques immuns chroniques
|
JP2014500879A
(ja)
*
|
2010-11-16 |
2014-01-16 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Bcma発現に相関性を有する疾患を治療する因子及び方法
|
CN107699585A
(zh)
|
2010-12-09 |
2018-02-16 |
宾夕法尼亚大学董事会 |
嵌合抗原受体‑修饰的t细胞治疗癌症的用途
|
JOP20210044A1
(ar)
|
2010-12-30 |
2017-06-16 |
Takeda Pharmaceuticals Co |
الأجسام المضادة لـ cd38
|
WO2012129514A1
(fr)
|
2011-03-23 |
2012-09-27 |
Fred Hutchinson Cancer Research Center |
Méthodes et compositions pour une immunothérapie cellulaire
|
US20130101599A1
(en)
|
2011-04-21 |
2013-04-25 |
Boehringer Ingelheim International Gmbh |
Bcma-based stratification and therapy for multiple myeloma patients
|
US8398282B2
(en)
|
2011-05-12 |
2013-03-19 |
Delphi Technologies, Inc. |
Vehicle front lighting assembly and systems having a variable tint electrowetting element
|
EP3415531B1
(fr)
|
2011-05-27 |
2023-09-06 |
Glaxo Group Limited |
Protéines de liaison à bcma (cd269/tnfrsf17)
|
WO2013006490A2
(fr)
|
2011-07-01 |
2013-01-10 |
Cellerant Therapeutics, Inc. |
Anticorps se liant spécifiquement à tim3
|
WO2013039954A1
(fr)
|
2011-09-14 |
2013-03-21 |
Sanofi |
Anticorps anti-gitr
|
WO2013054320A1
(fr)
|
2011-10-11 |
2013-04-18 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Anticorps dirigés contre la molécule d'adhésion cellulaire associée à l'antigène carcino-embryonnaire (ceacam)
|
WO2013071154A1
(fr)
|
2011-11-11 |
2013-05-16 |
Fred Hutchinson Cancer Research Center |
Immunothérapie par des lymphocytes t ciblant la cycline a1 pour le traitement du cancer
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對bcma之e3以及cd3的結合分子
|
ES2753614T3
(es)
|
2011-12-01 |
2020-04-13 |
Brigham & Womens Hospital Inc |
Anticuerpos recombinantes anti-CEACAM1 para terapia contra el cáncer
|
WO2013109759A1
(fr)
|
2012-01-17 |
2013-07-25 |
Northeastern University |
Méthodes et compositions de développement in vitro de lymphocytes t régulateurs immunosuppresseurs et utilisations de celles-ci
|
US9447194B2
(en)
|
2012-02-13 |
2016-09-20 |
Seattle Children's Hospital |
Bispecific chimeric antigen receptors and encoding polynucleotides thereof
|
WO2013126726A1
(fr)
|
2012-02-22 |
2013-08-29 |
The Trustees Of The University Of Pennsylvania |
Lymphocytes t doubles transgéniques comportant un car et un tcr, et leurs procédés d'utilisation
|
KR20220029757A
(ko)
|
2012-04-11 |
2022-03-08 |
더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 |
B-세포 성숙 항원을 표적화하는 키메라 항원 수용체
|
CN107557334B
(zh)
|
2012-05-03 |
2021-06-25 |
弗雷德哈钦森癌症研究中心 |
增强亲和力的t细胞受体及其制备方法
|
EP2674439B1
(fr)
|
2012-06-13 |
2017-02-01 |
Rottapharm Biotech S.r.l. |
Anticorps anti-TrkA, dérivés et utilisations associés
|
EP2879709B1
(fr)
|
2012-07-31 |
2020-01-08 |
The Brigham and Women's Hospital, Inc. |
Modulation de la réponse immunitaire
|
IL269270B
(en)
|
2012-08-20 |
2022-07-01 |
Hutchinson Fred Cancer Res |
Method and preparations for cellular immunotherapy
|
KR102198058B1
(ko)
|
2012-10-02 |
2021-01-06 |
메모리얼 슬로안 케터링 캔서 센터 |
면역치료용 조성물 및 방법
|
BR112015008118A2
(pt)
|
2012-10-12 |
2017-12-05 |
Brigham & Womens Hospital Inc |
reforço da resposta imune
|
US9243058B2
(en)
|
2012-12-07 |
2016-01-26 |
Amgen, Inc. |
BCMA antigen binding proteins
|
TW201425336A
(zh)
|
2012-12-07 |
2014-07-01 |
Amgen Inc |
Bcma抗原結合蛋白質
|
WO2014087010A1
(fr)
|
2012-12-07 |
2014-06-12 |
Ablynx N.V. |
Polypeptides améliorés dirigés contre ige
|
US9405601B2
(en)
|
2012-12-20 |
2016-08-02 |
Mitsubishi Electric Corporation |
In-vehicle apparatus and program
|
LT2961831T
(lt)
|
2013-02-26 |
2020-11-10 |
Memorial Sloan Kettering Cancer Center |
Kompozicijos ir būdai, skirti imunoterapijai
|
DK3309248T3
(da)
|
2013-05-29 |
2021-08-02 |
Cellectis |
Fremgangsmåde til manipulering af T-celler til immunterapi under anvendelse af et RNA-guidet CAS-nuklease-system
|
AR096687A1
(es)
|
2013-06-24 |
2016-01-27 |
Genentech Inc |
Anticuerpos anti-fcrh5
|
US9108442B2
(en)
|
2013-08-20 |
2015-08-18 |
Ricoh Company, Ltd. |
Image forming apparatus
|
US9512084B2
(en)
|
2013-11-29 |
2016-12-06 |
Novartis Ag |
Amino pyrimidine derivatives
|
ES2903155T3
(es)
|
2013-12-06 |
2022-03-31 |
Celgene Corp |
Métodos para determinar la eficacia del fármaco para el tratamiento de linfoma difuso de células B grandes, mieloma múltiple y cánceres mieloides
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
US20150259420A1
(en)
|
2014-03-14 |
2015-09-17 |
Novartis Ag |
Antibody molecules to lag-3 and uses thereof
|
EP3593812A3
(fr)
|
2014-03-15 |
2020-05-27 |
Novartis AG |
Traitement du cancer à l'aide d'un récepteur d'antigène chimérique
|
EP3129470B1
(fr)
|
2014-04-07 |
2021-04-07 |
Novartis Ag |
Traitement du cancer à l'aide du récepteur antigénique chimérique anti-cd19
|
JP6765968B2
(ja)
|
2014-04-10 |
2020-10-07 |
シアトル チルドレンズ ホスピタル, ディービーエー シアトル チルドレンズ リサーチ インスティテュート |
薬物制御による導入遺伝子の発現
|
EP3131927B8
(fr)
|
2014-04-14 |
2020-12-23 |
Cellectis |
Récepteurs antigéniques chimériques spécifiques de bcma (cd269), utiles dans l'immunothérapie du cancer
|
TWI750110B
(zh)
|
2014-07-21 |
2021-12-21 |
瑞士商諾華公司 |
使用人類化抗-bcma嵌合抗原受體治療癌症
|
WO2016014530A1
(fr)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Combinaisons de faibles doses renforçant l'immunité d'inhibiteurs de mtor et car
|
SG10201900931XA
(en)
|
2014-12-05 |
2019-02-27 |
Memorial Sloan Kettering Cancer Center |
Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
|
AU2015357533B2
(en)
|
2014-12-05 |
2021-10-07 |
Eureka Therapeutics, Inc. |
Antibodies targeting B-cell maturation antigen and methods of use
|
HUE057777T2
(hu)
|
2014-12-05 |
2022-06-28 |
Memorial Sloan Kettering Cancer Center |
Kiméra antigén receptorok, amelyek G-fehérje-kapcsolt receptort céloznak meg, és a receptorok alkalmazásai
|
LT3230321T
(lt)
*
|
2014-12-12 |
2019-12-10 |
Bluebird Bio Inc |
Bcma chimeriniai antigeno receptoriai
|
US9713375B1
(en)
|
2015-02-26 |
2017-07-25 |
Brett Einar Rahm |
Collapsible portable table
|
WO2017222593A1
(fr)
|
2016-06-24 |
2017-12-28 |
Icell Gene Therapeutics Llc |
Récepteurs d'antigènes chimériques (car), compositions et procédés associés
|
JP2018527302A
(ja)
|
2015-06-26 |
2018-09-20 |
セルジーン コーポレイション |
免疫調節化合物を用いたカポジ肉腫またはkshv誘発性リンパ腫の治療方法、及びバイオマーカーの使用
|
MA53750A
(fr)
|
2015-08-17 |
2021-09-15 |
Janssen Pharmaceutica Nv |
Anticorps anti-bcma, molécules de liaison d'antigène bispécifiques qui se lient au bcma et cd3 et leurs utilisations
|
US11747346B2
(en)
|
2015-09-03 |
2023-09-05 |
Novartis Ag |
Biomarkers predictive of cytokine release syndrome
|
WO2017058754A1
(fr)
|
2015-09-28 |
2017-04-06 |
Celgene Corporation |
Multithérapie pour le traitement de cancers hématologiques et de tumeurs solides
|
US20180346571A1
(en)
|
2015-11-17 |
2018-12-06 |
Oncomed Pharmaceuticals, Inc. |
Pd-l1-binding agents and uses thereof
|
WO2017172981A2
(fr)
|
2016-03-29 |
2017-10-05 |
University Of Southern California |
Récepteurs antigéniques chimériques ciblant le cancer
|
KR20220133318A
(ko)
|
2016-04-15 |
2022-10-04 |
노파르티스 아게 |
선택적 단백질 발현을 위한 조성물 및 방법
|
ES2916335T3
(es)
|
2016-10-20 |
2022-06-30 |
Celgene Corp |
Receptores de antígeno quimérico heterodimerizable basados en cereblon
|
US20200055948A1
(en)
|
2017-04-28 |
2020-02-20 |
Novartis Ag |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
WO2018197675A1
(fr)
|
2017-04-28 |
2018-11-01 |
Julius-Maximilians-Universität Würzburg |
Récepteurs antigéniques chimériques (car) spécifiques à ror1 ayant des domaines de ciblage humanisés
|
JP7299841B2
(ja)
|
2017-05-01 |
2023-06-28 |
ジュノー セラピューティクス インコーポレイテッド |
細胞療法と免疫調節化合物の併用
|
BR112020008638A2
(pt)
|
2017-11-01 |
2020-10-20 |
Juno Therapeutics Inc |
receptores de antígenos quiméricos específicos para antígenos de maturação de células b (bcma)
|
MX2020004568A
(es)
|
2017-11-06 |
2020-10-05 |
Juno Therapeutics Inc |
Combinación de una terapia celular y un inhibidor de gamma secretasa.
|
CN108239144B
(zh)
|
2018-01-26 |
2021-05-25 |
重庆精准生物技术有限公司 |
改造的铰链及其在构建car骨架中的应用
|
WO2020092854A2
(fr)
|
2018-11-01 |
2020-05-07 |
Juno Therapeutics, Inc. |
Récepteurs antigéniques chimériques spécifiques du gprc5d (élément d du groupe 5 de classe c des récepteurs couplés à la protéine g)
|
JP2023504740A
(ja)
|
2019-12-06 |
2023-02-06 |
ジュノー セラピューティクス インコーポレイテッド |
Bcma標的結合ドメインに対する抗イディオタイプ抗体ならびに関連する組成物および方法
|